Anti-Tumor Activity and Biomarker Analysis for TROP2-Antibody Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

0
23
Scientists tested the activity of datopotamab deruxtecan in a panel of breast cancer patient-derived xenografts varying in TROP2 expression.
[Clinical Cancer Research]
Abstract